Welcome to our dedicated page for Elevation Oncolo SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access archived SEC filings for Elevation Oncology, Inc. (ELEV), a former precision oncology company that was acquired by Concentra Biosciences. These historical regulatory documents provide a record of the company's financial disclosures and corporate events during its time as a NASDAQ-listed entity.
Elevation Oncology's filing history reflects the typical disclosure patterns of a clinical-stage biopharmaceutical company. Quarterly 10-Q and annual 10-K reports documented cash burn rates, research and development expenses for the seribantumab program, and the financial requirements of conducting clinical trials for rare cancer indications. For biotech investors studying similar companies, these filings offer insight into how precision oncology firms structure their financial disclosures.
The company's 8-K filings chronicle material events including pipeline updates, strategic decisions like the discontinuation of certain drug programs, and ultimately the acquisition by Concentra Biosciences. Form 4 insider trading filings show executive transactions during the company's public trading period.
The filing archive concludes with the Form 25-NSE confirming NASDAQ delisting and Form 15-12G terminating SEC reporting obligations following the acquisition. Researchers interested in biotech M&A transactions can review the SC 14D9 tender offer recommendation documents for details on the acquisition process.
Our AI-powered summaries help explain complex clinical-stage biotech disclosures, making it easier to understand R&D cost structures, cash runway calculations, and the regulatory filing requirements specific to companies developing drugs for rare genetic alterations like NRG1 fusions.
Elevation Oncology, Inc. Schedule 13G/A discloses that Tang Capital entities and Kevin Tang beneficially own 3,115,000 shares of common stock, representing 4.997% of the class on a fully-diluted basis. The 3,115,000 shares are currently issuable upon exercise of warrants that are immediately exercisable and expire five years from issuance. The filing states the 62,338,729-share denominator used (59,223,729 outstanding as of May 9, 2025 plus 3,115,000 warrants). Voting and dispositive power over these shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang. The filing affirms these holdings are not for control purposes.
Several Frazier Life Sciences funds and named individuals filed a Schedule 13G/A reporting that they hold no beneficial ownership of Elevation Oncology common stock. Each Reporting Person discloses 0.00 shares and 0.0% of the class, with zero sole or shared voting power and zero sole or shared dispositive power. The statement includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer.
The filing identifies the reporting entities as multiple Frazier Life Sciences partnerships and affiliated entities and names the Members as James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes. A Joint Filing Agreement is incorporated by reference. Given the reported aggregate ownership of zero, this disclosure does not change the companys ownership or voting structure.
BML Investment Partners, L.P. has filed Amendment No. 1 to Schedule 13D regarding its prior position in Elevation Oncology, Inc. (ELEV). The filing states that, as of 23 July 2025, a Merger Agreement was consummated through a tender offer by an unaffiliated “Merger Sub” that purchased all outstanding shares of Elevation Oncology common stock. Following the closing, BML Investment Partners reports 0 shares beneficially owned, representing 0 % of the class.
• Voting and dispositive power: 0 shares sole or shared.
• Source of funds: “WC” (working capital) is listed, but no new capital was deployed as the position has been exited.
• No contracts, arrangements, or legal proceedings related to the securities are disclosed, and the reporting persons confirm no criminal or civil violations within the past five years.
The amendment principally serves to formally terminate BML’s reporting obligations by documenting its complete divestiture after the successful tender offer.
FAQ
What is the current stock price of Elevation Oncolo (ELEV)?
What is the market cap of Elevation Oncolo (ELEV)?
